Go Back
MARINUS PHARMACEUTICALS, INC. reports $34.7 million Q1 loss
By USInMinutes - May 11, 2023, 10:36 AM ET
Last Updated - Jul 18, 2023, 03:31 PM EDT
The company generated $10.40 million in quarterly revenue
MARINUS PHARMACEUTICALS, INC. [MRNS] has reported fiscal Q1 loss of $34.70 million.
On a per-share basis, the DE based company said its diluted earnings are $0.67.
The Pharmaceutical Preparations firm posted revenue of $10.40 million in this period.
Also Read:
- Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
- Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 11, 2023
- Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome
- Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
NewsInMinutes is an offering of 10kInfo, Inc., bringing you news on the latest regulatory filings. You may subscribe to news alerts here.
Sponsored
Sponsored
Read More from Investing
Popular News
Latest News
